CSI Market
Sign In | Register

Interpace Biosciences Inc (PDII) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PDII Annual Cash Flow →
From Interpace Biosciences Inc through Jun 30 2025, changes in Jun 30 2026's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income2.28
Depreciation & amortization0.25
Amortization of Other Assets0.00
Accretion Expense0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.01
Income (Loss) from Equity Method Investments-1.10
Fair Value Adjustment of Warrants0.00
Other Intangible Assets Net-
Derivative Gain Loss On Derivative Net-
Reversal Of Doj Accrual-
Reversal Of Severance Accrual-
Reversal Of Accrual-
Reversal Of Bonus Accrual-
Amortization Of Loan Costs-
Interest Expense Debt-
Increase Decrease In Accrued Salaries And Bonus-1.17
Accrued Interest Related Parties-
Accrued Interest Notes Payable-
Employee Stock Purchase Plan Expense-
Bad Debt Expense Reversal-
Increase Decrease In Operating Lease Liability-0.13
Increase Decrease In Other Longterm Assets-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.66
Increase (Decrease) in Accounts Payable0.33
Increase (Decrease) in Other Accrued Liabilities0.23
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Deferred Income Taxes0.00
Other Working Capital0.66
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-2.71
Discontinued operations-0.22
Net Cash flow from Operating Activities0.38
Investing Activities
Capital Expenditures-0.20
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Sales Of Equity Method Investments-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans and Leases0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Proceeds from Sale of Equity Method Investments0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.20
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Treasury Stock Value Acquired Cost Method-
Payments Of Contingent Consideration-
Payments Of Treasury Stock-
Exercise Of Warrants Net Of Expenses-
Payment Of Sellers Note-
Proceeds From Issuance Of Preferred Stock And Preference Stocks-
Payment Of Sellers Note Note And Related Interest-
Proceeds From Loan-
Payments For Loan-
Financing Fees Related Party-
Loan Proceeds-
Loan Expenses-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow0.18
Total Cash Flow0.18
4 historic quarters locked

Sign in to unlock the full Interpace Biosciences Inc cash flow history.

Sign In Create Free Account

About Interpace Biosciences Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 10, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-036895

Figures are derived from filed reports and may be restated. Historical data is subject to revision.